Intraductal Papillary Mucinous Neoplasms of the Pancreas (IPMNs): Epidemiology, Diagnosis and Future Aspects

  • Froso Konstantinou Oncology Unit, Third Department of Medicine, Athens School of Medicine, Sotiria General Hospital. Athens, Greece
  • Konstantinos N Syrigos Oncology Unit, Third Department of Medicine, Athens School of Medicine, Sotiria General Hospital. Athens, Greece
  • Muhammad Wasif Saif Department of Medicine and Cancer Center, Tufts Medical Center. Boston, MA, USA
Keywords: Carcinoma, Pancreatic Ductal, Chemotherapy, Adjuvant, Disease Management, Early Diagnosis, Incidence, Follow-Up Studies, Neoplasms, Cystic, Mucinous, and Serous, Pancreas

Abstract

Intraductal papillary mucinous neoplasms of the pancreas (IPMNs) are potentially malignant intraductal epithelial neoplasms which consist of columnar, mucin-containing cells and arise from the epithelium of the main pancreatic duct or its branches. IPMNs as well as pancreatic intraepithelial neoplasias (PanINs) and mucinous cystic neoplasms represent noninvasive precursors of invasive ductal adenocarcinoma of the pancreas. The diagnosis of IPMNs includes radiographic (CT scanning, MRI, MRCP) and endoscopic evaluation (ERCP, EUS), PET, as well as serum tumor markers and molecular markers. The Sendai Consensus Guidelines help guide surgical resection for patients with IPMN. The follow-up of these patients, as well as of those who do not undergo surgical resection, is of great importance, since patients with IPMN appear to be at risk for other malignancies. Herein, the authors summarize the data presented at the 2013 ASCO Gastrointestinal Cancers Symposium regarding incidence and clinicopathological characteristics of IPMN (Abstracts #324, #187 and #179).

Image: "Sotiria" ("Salvation") Hospital (Athens, Greece) logo. (Sophia Engastromenou Schliemann, founder of the hospital in 1902).

Downloads

Download data is not yet available.

References

Grützmann R, Niedergethmann M, Pilarsky C, et al. Intraductal Papillary Mucinous Tumors of the Pancreas: Biology, Diagnosis and Treatment. Oncologist.2010;15(12):1294

Freeman HJ. Intraductal papillary mucinous neoplasms and other pancreatic cystic lesions. World J Gastroenterol.2008;14(19):2977

Klibansky DA, Reid-Lombardo KM, Gordon SR, Gardner TB. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol.2012;10(5):555

Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology.2006;6(1-2):17

Kobari M, Egawa S, Shibuya K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg.1999;134(10):1131

Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol.2000;24(10):1372

Nagai K, Doi R, Kida A, et al. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathologic characteristics and long-term follow-up after resection. World J Surg.2008;32(2):271

Sugiyama M, Atomi Y. Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol.1999;94(2):470

Choi MG, Kim SW, Han SS, et al. High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. Arch Surg.2006;141(1):51

Kamisawa T, Tu Y, Egawa N, et al. Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas. World J Gastroenterol.2005;11(36):5688

Luu C, Nelson RA, Lee B, Singh G, Kim J. Evaluating malignant intraductal papillary mucinous neoplasm: A population-based study. J Clin Oncol.2012;30: Abstract 324

Einama T, Kamachi H, Nishihara H, Homma S, Kawamata F, Tahara M, Taniguchi M, Furukawa H, Kamiyama T, Taketomi A, Matsuno Y, Todo S. Clinical implications of luminal membrane expression of mesothelin in intraductal papillary mucinous neoplasms. J Clin Oncol.2012; 30 (Suppl. 34): Abstarct #179.

Eto T, Hayashi H, Kuroki H, Nakagawa S, Hashimoto D, Ikuta Y, Chikamoto A, Beppu T, Baba H. Association of dilated main pancreatic duct with biological high proliferative activity in intraductal papillary mucious neoplasm. J Clin Oncol.2012;30: Abstarct 187

Grützmann R, Bunk A, Kersting S, et al. Prospective evaluation of ultrasound and colour duplex imaging for the assessment of surgical resectability of pancreatic tumors. Langenbecks Arch Surg.2003;388:392

Brugge WR. The use of EUS to diagnose cystic neoplasms of the pancreas. Gastrointest Endosc.2009;69(2 suppl):S203

Sahani DV, Kadavigere R, Blake M, et al. Intraductal papillary mucinous neoplasm of the pancreas: Multi-detector row CT with 2D curved reformations-correlation with MRCP. Radiology.2006;238:560

Yamada Y, Mori H, Matsumoto S. Intraductal papillary mucinous neoplasms of the pancreas: Correlation of helical CT and dynamic MR imaging features with pathologic findings. Abdom Imaging.2008;33:474

Baiocchi GL, Portolani N, Bertagna F, et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: Preliminary results. J Exp Clin Cancer Res.2008;27:10

Fritz S, Hackert T, Hinz U, et al. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg.2011;98(1):104

Maker AV, Katabi N, Gonen M, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol.2011;18(1):199

Hong SM, Kelly D, Griffith M, Omura N, Li A, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Modern Pathology.2008;21:1499

Furukawa T, Fujisaki R, Yoshida Y, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms of the pancreas. Modern Pathology.2005;18:1034

Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther.2009;8(4):340

Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int.1997;47(12):813

Yonezawa S, Horinouchi M, Osako M, et al. Gene expression of gastric type mucin (MUC5AC) in pancreatic tumors: its relationship with the biological behavior of the tumor. Pathol Int.1999;49(1):45

Swartz MJ, Hsu CC, Pawlik TM, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys.2010;76(3):839

Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg.2004;239(6):788

Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology.2002;123(5):1500

Murakami Y, Uemura K, Sudo T, et al. Invasive intraductal papillary mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol.2009;100(1):13

Sotiria General Hospital. Athens, Greece
Published
2013-03-10
How to Cite
Konstantinou, F., Syrigos, K., & Saif, M. (2013). Intraductal Papillary Mucinous Neoplasms of the Pancreas (IPMNs): Epidemiology, Diagnosis and Future Aspects. JOP. Journal of the Pancreas, 14(2), 141-144. https://doi.org/10.6092/1590-8577/1467
Section
Highlights from the “2013 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 24-26, 2013

Most read articles by the same author(s)

1 2 > >>